Qpex Biopharma Joins Antimicrobials Working Group

WASHINGTON, Oct. 30, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Qpex Biopharma, Inc. (Qpex) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Qpex is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. The company has an established research and development (R&D) partnership with Biomedical Advanced Research and Development Authority (BARDA) that provides the potential to support the development of a portfolio of new antibiotics to fight drug-resistant, gram-negative infections.

The new addition brings AWG's membership to 18 antimicrobial drug and diagnostic device development companies.

"Qpex Biopharma has a strong pipeline of drug candidates and a management team with a record of success in the discovery, development and regulatory approval of anti-infective medicines to help address the worldwide problem of antimicrobial resistance," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics and Chairman of AWG. "Qpex is an excellent example of an early stage biotech company leading the charge of R&D to fill the future pipeline of anti-infectives, and we believe Qpex's experience will be a great benefit to our coalition's efforts to improve the landscape for emerging infectious disease companies."

"Small biotechnology companies like Qpex have been the engine for the discovery, development, and regulatory approval of new treatments for infectious diseases," said Michael Dudley, PharmD, president and chief executive officer of Qpex Biopharma. "We are partnering with AWG and our industry peers to advance initiatives to overcome the economic challenges facing innovative and commercially-emergent companies that are critical for ensuring future availability of life-saving therapies to patients and providers."

All pharmaceutical and biotechnology companies developing new antimicrobial therapeutics and diagnostic devices are eligible for consideration of membership in AWG. If you are interested in learning more about becoming a member of AWG, please contact us here.

About Qpex BioPharma, Inc.

Qpex Biopharma is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. Qpex management has a record of deep expertise in the discovery, development and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance.

About The Antimicrobials Working Group

AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of eighteen antimicrobials and diagnostics companies: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis Inc., Cidara Therapeutics Inc., ContraFect Corporation, Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics Inc., Motif Bio PLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., Qpex Biopharma, Inc., SCYNEXIS Inc., Spero Therapeutics, Inc., Summit Therapeutics plc, T2 Biosystems Inc., Theravance Biopharma U.S. Inc. and Vical Incorporated.

For more information, visit: www.antimicrobialsworkinggroup.org

About The Conafay Group

The Conafay Group, led by Stephen R. Conafay, Principal, is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for AWG.

For more information, visit: www.conafaygroup.com

SOURCE Antimicrobials Working Group (AWG)

Related Links

https://www.antimicrobialsworkinggroup.org